Microsoft word - abortion and women's health_a selected bibliography.doc
Abortion and Women’s Health – A Selected Bibliography (June 2010)
LexisNexis® Statistical Insight
“Caring for Women with Abortion Complications in Ethiopia: National Estimates and Future
Implications,” International Perspectives on Sexual and Reproductive Health. Alan Guttmacher
Institute, pp. 6-15.
2010 SRI A5160-6.402.1
Covers abortion complications and post-abortion care in Ethiopia. Data are from a study of
1,932 women seeking post-abortion care at 344 public and private health facilities, and a survey
of staff at 337 health facilities; data were collected Nov. 2007-Mar. 2008.
Abortion in the Middle East and North Africa, Population Reference Bureau, Sept. 2008, 8 pp.
2008 SRI R8750-41.15
Middle East and North Africa abortions, women’s contraception use and unmet family planning
needs, and deaths from unsafe abortions, for region and selected countries, with international
comparisons, 2008 rpt.
Determinants of Induced Abortion and Its Consequences on Women’s Reproductive Health:
Findings from India's National Family Health Surveys, Agency for International Development,
Aug. 2008, 67 pp.
2008 ASI 9916-42.13, PDF Available
India abortions among ever-married women aged 15-49 and reproductive health problems, by
selected characteristics, 2008 working paper.
Abortion and Women’s Health: A Turning Point for America? Alan Guttmacher Institute, 1990,
1991 SRI A5160-8
Report presenting an overview of abortion in the U.S. in the 1980s, and discussing implications
of restricted access to abortion. Data are from studies previously published by the Alan
Guttmacher Institute, and other specified sources.
Medical and Psychological Impact of Abortion, House Government Operations Committee, Mar.
16, 1989, 346 pp.
1989 ASI 21408-113
Hearing held Mar. 1989 before the Subcommittee on Human Resources and Intergovernmental
Relations to examine medical and psychological effects of abortion. Abortions by patient
characteristics, rates for all and 1st abortions, and related deaths in US and other countries, 1989
LexisNexis® Statistical Datasets
“Type – Urgent”, Agency for Healthcare Research and Quality [data file] (2009). LexisNexis
Statistical Datasets (06/09/2010).
Indicator: Type- Urgent; Diagnosis: Complications following abortion and ectopic and molar
pregnancies, 2001-2006. Committee Prints and CRS Reports (LexisNexis® Congressional Research Digital
CRS Issue Statement on Abortion, Family Planning, and Reproductive Health, Jan. 11, 2010,
Outlines background on and history of abortion, family planning, and reproductive health
legislation and litigation, reviewing current issues for Congress.
FDA and RU-486: Lowering the Standard for Women's Health,
Oct. 2006, 40 pp.
Staff report examining FDA approval process for the abortion drug mifepristone, also known as
Mifeprex and RU-486, and reviewing related safety and women's health issues.
False and Misleading Health Information Provided by Federally Funded Pregnancy Resource
Centers, July 2006, 18 pp.
Minority staff report summarizing findings on the scientific inaccuracy of information provided
by pregnancy resource centers funded by the Bush Administration, focusing on centers provision
of false and misleading information about abortions. LexisNexis® Congressional Hearings Digital Collection
Melanie Blocker-Stokes Postpartum Depression Research and Health Care Act, May 1, 2007,
Hearing before the Subcom on Health to consider H.R. 20, the Melanie Blocker-Stokes
Postpartum Depression Research and Care Act, to encourage HHS to continue research and
dissemination of information concerning postpartum depression or psychosis. Also examines
post-abortion mental disorders.
RU-486: Demonstrating a Low Standard for Women's Health?, May 17, 2006, 640 pp.
Hearing before the Subcom on Criminal Justice, Drug Policy, and Human Resources to examine
safety and women's health issues related to the abortion drug mifepristone, also known as
Mifeprex and RU-486, in light of recent deaths of women who used the drug.
Scope and Myths of Roe V. Wade, Vol. II, Mar. 2, 2006, 1059 pp.
Continuation of hearing before the Subcom on the Constitution to examine legal issues and
societal effects relating to Supreme Court decision in Roe v. Wade, which established a woman's
constitutional right to obtain an abortion.
Scope and Myths of Roe V. Wade, Vol. I, Mar. 2, 2006, 1157 pp.
Hearing before the Subcom on the Constitution to examine legal issues and societal effects
relating to Supreme Court decision in Roe v. Wade , which established a woman's constitutional
right to obtain an abortion. Also examines concerns about impact of abortion on women's
emotional and mental health and importance of Roe v. Wade in terms of women's rights and
Improving Women's Health: Understanding Depression After Pregnancy, Sept. 29, 2004, 67 pp.
Hearing before the Subcom on Health to examine problem of postpartum and post-abortion
depression in women. Reports and Documents (LexisNexis® Serial Set Digital Collection)
Partial-Birth Abortion Ban Act of 1997, Mar. 14, 1997, 37 pp.
Recommends passage, with an amendment in the nature of a substitute, of H.R. 929, the Partial-
Birth Abortion Ban Act of 1997, to establish criminal penalties and civil liability for persons who
perform certain late-term abortion procedures, unless the procedures are necessary to prevent
Federal Role in Determining the Medical and Psychological Impact of Abortion on Women,
Dec. 11, 1989, 36 pp.
Report, based on Subcom on Human Resources and Intergovernmental Relations study and Mar.
16, 1989 hearing, examining medical and psychological effects of abortion.
LexisNexis® Government Periodicals Index
“Residential Exposure to Traffic and Spontaneous Abortion,” Environmental Health
Perspectives, National Institute of Environmental Health Sciences, Dec. 2009, Vol. 117:Iss. 12,
“Clostridium sordellii Toxic Shock Syndrome After Medical Abortion with Mifepristone and
Intravaginal Misoprostol--United States and Canada, 2001-2005,” Morbidity and Mortality
Weekly Report, Centers for Disease Control and Prevention, July 29, 2005, Vol. 54:Iss. 29,
724 pp. To find related publications or to expand your research in this area, try these
subject headings and key words:
SUMMARY OF THE PRODUCT CHARACTERISTICS NAME OF THE MEDICINAL PRODUCT Novastan 100 mg/ml concentrate for solution for infusion. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml concentrate for solution for infusion contains 100 mg argatroban. 1 Vial with 2.5 ml concentrate for solution for infusion contains 250 mg argatroban. Final concentration after dilution as recommended is 1 mg/ml
ADDIS ABABA UNIVERSITY Framework Document Reforming Academic Governance February 2011 I. Introduction In the academic arena, the reform process at AAU has now reached a stage where the following have been successfully accomplished: 1. Definition of the university-wide structure for academic administration 2. Establishment of all academic units and university-wide academic o